US Patent 7220721 Exendin agonist peptides
Patent 7220721 was granted and assigned to Amylin Pharmaceuticals on May, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 14 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 6 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Kathryn S. Prickett0
Nigel R. Beeley0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+220 characters)
Article
Patent abstract
Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07220721 Exendin agonist peptides US Patent 7220721 Exendin agonist peptides
Infobox
Patent Number
072207210
Patent Number
72207210
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072207210
Date of Patent
May 22, 2007
0Patent Application Number
095545310
Date Filed
November 13, 1998
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 21 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07220721 Exendin agonist peptides
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07220721
Date of patent
May 22, 2007
Patent application number
09554531
Date Filed
November 13, 1998
Patent primary examiner
Find more entities like US Patent 7220721 Exendin agonist peptides
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
